Barbara Ryan
Barbara Ryan
Barbara Ryan Colemanis a fictional character from the American CBS soap opera As the World Turns. In the early 1970s, Barbara was played by a succession of actresses, but the actress most associated with the role is Colleen Zenk, who played her since September 1, 1978. Better known as simply Barbara Ryan she is portrayed as a heroine who experienced many tragedies, mostly at the hands of her controlling ex-husband, the villainous James Stenbeck...
companies strong survive
Strong companies are going to survive in this sector, and they're going to look more like Pfizer than not.
anyone becoming environment helped labels people
That hasn't helped anyone much. We're in an environment now where labels are becoming so riddled with warnings that people don't know what to do.
heroic stretch
The restructuring is not heroic by any stretch of the imagination.
business good price
They can get a good price for it and it's probably undervalued in their portfolio. It's not so much about them getting out of that business much as it's about unleashing shareholder value.
based cost earnings expect recovery year
Bristol-Myers earnings will be down this year but then we expect to see a recovery based on the introduction of new drugs and cost cuts.
aided company deliver despite earnings faced pressures top
Despite the pressures that Pfizer has faced and will face on the top line, the company will be able to deliver on their earnings target, in part aided by introduction of their new drugs.
clear detail heard humbled loud management recognize team
You're going to see a much more transparent and humbled management team with a lot more detail and granularity on a whole lot of issues, which is not characteristic of Pfizer historically. They have heard their shareholders loud and clear and recognize that they need to be transparent and more visible.
beyond both gets good patents victory won
This is as good as it gets for Pfizer. They won a victory on both patents -- well beyond our expectations.
altogether cash certainty clearly company disregard generic given greater industry litigation settle translate tremendous unlikely
Pfizer clearly is a company with tremendous disregard for the generic drug industry and is not given to settling. But it is not altogether unlikely that Pfizer could settle its litigation. If Pfizer could translate some of its cash hoards into greater certainty on this litigation ... I think they would do that.
appears economics far merger neutral quite revenue short somewhat stock trend
So far the integration appears to be going well. The economics of the merger are going to be quite strong. We're somewhat disappointed in the near-term revenue trend and are neutral on the stock in the short run.
behind cases modest positive
modest positive for the stock, modest because they have 6,000 cases behind this one.
billion build dollar few sales takes
New drugs are not going to build billion dollar sales in a few weeks. It takes years to do that.
huge market
Obviously, it's a huge market and it's growing.
currently fairly peers portfolio relative standing
Wyeth is really standing out relative to its peers currently because it has a fairly young portfolio of new drugs,